Eisai Co (TSE:4523) FCF Margin % : 0.60% (As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Eisai Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Eisai Co's Free Cash Flow for the three months ended in Dec. 2023 was 円1,073 Mil. Eisai Co's Revenue for the three months ended in Dec. 2023 was 円177,703 Mil. Therefore, Eisai Co's FCF Margin % for the quarter that ended in Dec. 2023 was 0.60%.

As of today, Eisai Co's current FCF Yield % is 1.99%.

The historical rank and industry rank for Eisai Co's FCF Margin % or its related term are showing as below:

TSE:4523' s FCF Margin % Range Over the Past 10 Years
Min: -4.88 Med: 10.28 Max: 20.82
Current: 4.76

During the past 13 years, the highest FCF Margin % of Eisai Co was 20.82%. The lowest was -4.88%. And the median was 10.28%.

TSE:4523's FCF Margin % is ranked better than
65.5% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs TSE:4523: 4.76

Eisai Co FCF Margin % Historical Data

The historical data trend for Eisai Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co FCF Margin % Chart

Eisai Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

11.84

7.56

5.53

10.20

-4.88

Eisai Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-7.50	8.73	2.07	7.51	0.60

Competitive Comparison of Eisai Co's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eisai Co's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Eisai Co's FCF Margin % falls into.

Eisai Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Eisai Co's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-36331	/	744402
	=	-4.88 %

Eisai Co's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1073	/	177703
	=	0.60 %

Eisai Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Eisai Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eisai Co (TSE:4523) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (TSE:4523) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ESAIY:USA ESALF:USA EII:Germany

Address

4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088

Website

http://www.eisai.co.jp

Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (TSE:4523) Headlines

No Headlines